Published in Nat Rev Cancer on March 01, 2011
Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2. Neoplasia (2012) 0.91
LPA Stimulates the Phosphorylation of p130Cas via Gαi2 in Ovarian Cancer Cells. Genes Cancer (2012) 0.85
NSP-CAS Protein Complexes: Emerging Signaling Modules in Cancer. Genes Cancer (2012) 0.84
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo". Oncotarget (2016) 0.75
Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer (2010) 2.94
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. Eur Urol (2010) 2.72
FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol (2008) 2.65
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer. Nat Genet (2008) 2.45
Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol (2005) 2.45
Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol (2008) 2.32
Ureteral and multifocal tumours have worse prognosis than renal pelvic tumours in urothelial carcinoma of the upper urinary tract treated by nephroureterectomy. Eur Urol (2011) 2.19
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet (2012) 2.18
Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility. Proc Natl Acad Sci U S A (2009) 1.81
Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol (2008) 1.70
Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol (2010) 1.56
Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol (2010) 1.52
Accuracy of the prostate health index versus the urinary prostate cancer antigen 3 score to predict overall and significant prostate cancer at initial biopsy. Prostate (2014) 1.48
Quantification of expression of netrins, slits and their receptors in human prostate tumors. Int J Cancer (2003) 1.45
Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene (2003) 1.43
Prospective, multidimensional evaluation of sexual disorders in men after laser photovaporization of the prostate. J Sex Med (2013) 1.42
Prostate-sparing cystectomy for bladder cancer: a step toward a dead-end. Urology (2010) 1.41
Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. BJU Int (2013) 1.40
[Role of endoscopy in the management of upper urinary tract tumors]. Prog Urol (2006) 1.39
A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Hum Mol Genet (2011) 1.34
Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet (2013) 1.34
The AdVance transobturator male sling for postprostatectomy incontinence: clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol (2009) 1.32
Tubulocystic carcinoma of the kidney: a new entity among renal tumors. Virchows Arch (2007) 1.25
Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. Clin Cancer Res (2007) 1.23
Fine mapping of a region of chromosome 11q13 reveals multiple independent loci associated with risk of prostate cancer. Hum Mol Genet (2011) 1.17
Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine. BJU Int (2011) 1.15
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology (2010) 1.13
A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol (2010) 1.13
Midterm prospective evaluation of TVT-Secur reveals high failure rate. Eur Urol (2010) 1.13
Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. J Clin Oncol (2007) 1.11
Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate (2002) 1.10
Mid-term evaluation of the transobturator male sling for post-prostatectomy incontinence: focus on prognostic factors. BJU Int (2010) 1.09
Association between estrogen and androgen receptor genes and prostate cancer risk. Eur J Endocrinol (2008) 1.06
Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology (2006) 1.04
Large-scale exploration of gene-gene interactions in prostate cancer using a multistage genome-wide association study. Cancer Res (2011) 1.03
Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol (2006) 1.02
Methylated genes as potential biomarkers in prostate cancer. BJU Int (2010) 1.02
Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol (2002) 1.01
Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res (2003) 1.00
Outcome after radical prostatectomy in young men with or without a family history of prostate cancer. Urology (2006) 1.00
Refining the prostate cancer genetic association within the JAZF1 gene on chromosome 7p15.2. Cancer Epidemiol Biomarkers Prev (2010) 0.99
Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer. Clin Cancer Res (2008) 0.99
8q24 amplification is associated with Myc expression and prostate cancer progression and is an independent predictor of recurrence after radical prostatectomy. Hum Pathol (2013) 0.98
Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. Int J Cancer (2008) 0.98
Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol (2010) 0.97
Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer. Prostate (2012) 0.97
Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol (2005) 0.96
Worry and attitude of men in at-risk families for prostate cancer about genetic susceptibility and genetic testing. Prostate (2002) 0.96
Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet (2015) 0.95
Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol (2002) 0.95
PGE2 and LTB4 tissue levels in benign and cancerous prostates. Prostaglandins Other Lipid Mediat (2008) 0.94
Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer (2004) 0.94
Large-scale fine mapping of the HNF1B locus and prostate cancer risk. Hum Mol Genet (2011) 0.94
Impact of prostate cancer screening on health-related quality of life in at-risk families. Urology (2002) 0.94
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease. Hum Genet (2013) 0.93
Adherence to an annual PSA screening program over 3 years for brothers and sons of men with prostate cancer. Eur Urol (2004) 0.93
Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol (2009) 0.93
Non-invasive molecular detection of bladder cancer recurrence. Int J Cancer (2002) 0.92
Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS One (2010) 0.92
BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining. Prostate (2007) 0.92
DNA-PKcs expression predicts response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys (2012) 0.92
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch (2015) 0.92
Does the surgical technique for management of the distal ureter influence the outcome after nephroureterectomy? BJU Int (2010) 0.92
Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. BJU Int (2009) 0.91
Extensive analysis of the 13q14 region in human prostate tumors: DNA analysis and quantitative expression of genes lying in the interval of deletion. Prostate (2003) 0.90
Region 2 of 8q24 is associated with the risk of aggressive prostate cancer in Caribbean men of African descent from Guadeloupe (French West Indies). Asian J Androl (2015) 0.90
Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother (2004) 0.90
Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels. Hum Genet (2011) 0.90
Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumours. World J Urol (2012) 0.90
The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol (2010) 0.89
Intravesical recurrence after radical nephroureterectomy for upper tract urothelial carcinomas: predictors and impact on subsequent oncological outcomes from a national multicenter study. World J Urol (2012) 0.89
Microsatellite instability in urothelial carcinoma of the upper urinary tract. J Urol (2003) 0.89
HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch (2013) 0.89
The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy. World J Urol (2012) 0.89
Molecular and histological markers in urothelial carcinomas of the upper urinary tract. BJU Int (2008) 0.88
Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. BJU Int (2008) 0.87
Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol (2003) 0.87
Management of lower urinary tract symptoms related to benign prostatic hyperplasia in real-life practice in france: a comprehensive population study. Eur Urol (2013) 0.86
Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR. Int J Cancer (2005) 0.86
Molecular profiling of benign prostatic hyperplasia using a large scale real-time reverse transcriptase-polymerase chain reaction approach. J Urol (2004) 0.85
Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate (2010) 0.85
Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer. Urology (2008) 0.85
Microsatellite instability and transitional cell carcinoma of the upper urinary tract. BJU Int (2005) 0.85
Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. Clin Nucl Med (2013) 0.85
Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology (2003) 0.84
[Clinical usefulness of positron emission tomography in prostate cancer]. Presse Med (2007) 0.84
Oncologic control obtained after radical prostatectomy in men with a pathological Gleason score ≥ 8: a single-center experience. Urol Oncol (2009) 0.84